Sequencing of Prostate Cancers Identifies New Cancer Genes, Routes of Progression and Drug Targets

Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer samples. From joint analysis of these cancers with those from previous studies (930 cancers in total), we found evidence for 22 previously unidentified putative driver genes harboring coding mutations, as well as evidence for NEAT1 and FOXA1 acting as drivers through noncoding mutations. Through the temporal dissection of aberrations, we identified driver mutations specifically associated with steps in the progression of prostate cancer, establishing, for example, loss of CHD1 and BRCA2 as early events in cancer development of ETS fusion-negative cancers. Computational chemogenomic (canSAR) analysis of prostate cancer mutations identified 11 targets of approved drugs, 7 targets of investigational drugs, and 62 targets of compounds that may be active and should be considered candidates for future clinical trials.

Citing Articles

Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers.

Dong B, Xu J, Huang Y, Guo J, Dong Q, Wang Y Nat Cancer. 2024; 5(9):1427-1447.

PMID: 39242942 DOI: 10.1038/s43018-024-00820-2.

Genomic landscape of early-stage prostate adenocarcinoma in Mexican patients: an exploratory study.

Cerrato-Izaguirre D, Gonzalez-Ruiz J, Diaz-Chavez J, Ramirez A, Scavuzzo A, Jimenez M Discov Oncol. 2024; 15(1):378.

PMID: 39196408 PMC: 11358564. DOI: 10.1007/s12672-024-01199-3.

Nurturing the marriages of urinary liquid biopsies and nano-diagnostics for precision urinalysis of prostate cancer.

Liao C, Wu Z, Lin C, Chen X, Zou Y, Zhao W Smart Med. 2024; 2(1):e20220020.

PMID: 39188554 PMC: 11236013. DOI: 10.1002/SMMD.20220020.

Prostate cancer detection through unbiased capture of methylated cell-free DNA.

Lleshi E, Milne-Clark T, Lee Yu H, Martin H, Hanson R, Lach R iScience. 2024; 27(7):110330.

PMID: 39055933 PMC: 11269940. DOI: 10.1016/j.isci.2024.110330.

scSemiProfiler: Advancing large-scale single-cell studies through semi-profiling with deep generative models and active learning.

Wang J, Fonseca G, Ding J Nat Commun. 2024; 15(1):5989.

PMID: 39013867 PMC: 11252419. DOI: 10.1038/s41467-024-50150-1.

References

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Attard G, Parker C, Eeles R, Schroder F, Tomlins S, Tannock I . Prostate cancer. Lancet. 2015; 387(10013):70-82. DOI: 10.1016/S0140-6736(14)61947-4. View

Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S . Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer. 2014; 110(6):1663-72. PMC: 3960610. DOI: 10.1038/bjc.2014.30. View

Loriot Y, Miller K, Sternberg C, Fizazi K, de Bono J, Chowdhury S . Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a.... Lancet Oncol. 2015; 16(5):509-21. DOI: 10.1016/S1470-2045(15)70113-0. View

Malinowska K, Neuwirt H, Cavarretta I, Bektic J, Steiner H, Dietrich H . Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer. 2008; 16(1):155-69. DOI: 10.1677/ERC-08-0174. View

Pilati C, Shinde J, Alexandrov L, Assie G, Andre T, Helias-Rodzewicz Z . Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. J Pathol. 2017; 242(1):10-15. DOI: 10.1002/path.4880. View

De Keersmaecker K, Atak Z, Li N, Vicente C, Patchett S, Girardi T . Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet. 2012; 45(2):186-90. PMC: 5547913. DOI: 10.1038/ng.2508. View

Collart M, Kassem S, Villanyi Z . Mutations in the Genes or in the Translation Machinery Similarly Display Increased Resistance to Histidine Starvation. Front Genet. 2017; 8:61. PMC: 5439007. DOI: 10.3389/fgene.2017.00061. View

Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K . Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat Med. 2011; 17(8):944-51. PMC: 4578312. DOI: 10.1038/nm.2392. View

10.

FitzGerald L, Patterson B, Thomson R, Polanowski A, Quinn S, Brohede J . Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease. Eur J Hum Genet. 2008; 17(3):368-77. PMC: 2986161. DOI: 10.1038/ejhg.2008.171. View

11.

Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S . Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013; 23(2):159-70. DOI: 10.1016/j.ccr.2013.01.002. View

12.

Fischer K, Pflugfelder G . Putative Breast Cancer Driver Mutations in TBX3 Cause Impaired Transcriptional Repression. Front Oncol. 2015; 5:244. PMC: 4625211. DOI: 10.3389/fonc.2015.00244. View

13.

Ryan C, Smith M, Fizazi K, Saad F, Mulders P, Sternberg C . Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3.... Lancet Oncol. 2015; 16(2):152-60. DOI: 10.1016/S1470-2045(14)71205-7. View

14.

Boutros P, Fraser M, Harding N, De Borja R, Trudel D, Lalonde E . Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015; 47(7):736-45. DOI: 10.1038/ng.3315. View

15.

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

16.

Carver B, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A . Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009; 41(5):619-24. PMC: 2835150. DOI: 10.1038/ng.370. View

17.

Rodrigues L, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M . Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 2015; 75(6):1021-34. PMC: 4531265. DOI: 10.1158/0008-5472.CAN-14-1596. View

18.

Patel M, Halling-Brown M, Tym J, Workman P, Al-Lazikani B . Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov. 2013; 12(1):35-50. DOI: 10.1038/nrd3913. View

19.

Van Loo P, Nordgard S, Lingjaerde O, Russnes H, Rye I, Sun W . Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A. 2010; 107(39):16910-5. PMC: 2947907. DOI: 10.1073/pnas.1009843107. View

20.

Cuzick J, Swanson G, Fisher G, Brothman A, Berney D, Reid J . Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011; 12(3):245-55. PMC: 3091030. DOI: 10.1016/S1470-2045(10)70295-3. View